878 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Roche's New Perjeta Combo Meets Goal in Breast Cancer Study http://www.zacks.com/stock/news/517413/roches-new-perjeta-combo-meets-goal-in-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-517413 Sep 13, 2019 - Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised) http://www.zacks.com/stock/news/516412/roche-reports-positive-data-on-tecentriq-nmosd-drug-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-516412 Sep 13, 2019 - Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
Renal Cell Carcinoma Space in Focus: Some Key Developments http://www.zacks.com/stock/news/516791/renal-cell-carcinoma-space-in-focus-some-key-developments?cid=CS-ZC-FT-analyst_blog|industry_focus-516791 Sep 13, 2019 - The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug http://www.zacks.com/stock/news/514866/roche-rhhby-reports-positive-data-on-tecentriq-ms-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-514866 Sep 12, 2019 - Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.
4 Big Drugmakers Boasting Impressive Oncology Pipelines http://www.zacks.com/stock/news/513001/4-big-drugmakers-boasting-impressive-oncology-pipelines?cid=CS-ZC-FT-analyst_blog|industry_focus-513001 Sep 11, 2019 - We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Buy 5 Top Dow Stocks to Gain From Index's Rally http://www.zacks.com/stock/news/510834/buy-5-top-dow-stocks-to-gain-from-indexs-rally?cid=CS-ZC-FT-analyst_blog|investment_ideas-510834 Sep 10, 2019 - The Dow is expected to maintain its current momentum for the rest of this month and further due to two immediate catalysts.
Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study http://www.zacks.com/stock/news/509890/lillys-ret-inhibitor-shrinks-tumors-in-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-509890 Sep 09, 2019 - Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs http://www.zacks.com/stock/news/505264/pharma-stock-roundup-agns-opioid-settlement-line-extension-nod-in-eu-for-mrk-jnj-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-505264 Sep 06, 2019 - Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study http://www.zacks.com/stock/news/505271/bristol-myers-bmy-opdivo-falls-flat-in-brain-tumor-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-505271 Sep 06, 2019 - Bristol-Myers (BMY) announces dismal results from a late-stage study on its immuno-oncology drug Opdivo for critical brain tumor.
Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer http://www.zacks.com/stock/news/505009/roches-tecentriq-combo-gets-eu-nod-for-difficult-lung-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-505009 Sep 06, 2019 - The latest EU nod makes Roche's (RHHBY) immuno-oncology drug -- Tecentriq -- the first and only cancer immunotherapy approved for the initial treatment of ES-SCLC in Europe.

Pages: 123456...88

Page 1>